Avacta Group presents promising Phase 1 clinical data for AVA6000 cancer treatment at ESMO Congress.

Avacta Group presented updated Phase 1 clinical data for AVA6000 at the ESMO Congress, revealing multiple ongoing and durable responses in patients with solid tumors. This announcement highlights the potential of AVA6000 as a promising treatment option in oncology, reflecting the company’s advancements in cancer therapies. The results may pave the way for further clinical development and research in this area.

September 14, 2024
4 Articles